We are launching a global, patient-led data bank, which will allow patients to unite in sharing their data, helping them to make better informed decisions about their own treatment plans, as well as helping vital research that could bring us closer to finding a cure.

The terminal illness charity is looking for applications that address its key research priorities identified by carers, health and social care professionals and people with terminal illness, and particularly, those areas that have until now received the least attention

St Andrew’s Fashion Show (FS) has raised over £28,000 for The Brain Tumour Charity in a bid to fund research in to vital treatments to tackle the disease.

Why a decision to cut benefits paid to bereaved parents is not in the interests of affected families.

Researchers from the Nottingham University’s children’s brain tumour centre are now looking into the effects of cannabidiol (CBD), the non-psychoactive ingredient in marijuana

An energetic team from global financial services technology company Ipreo will soon be taking on the gruelling Tough Mudder in support of The Brain Tumour Charity.

The Brain Tumour Charity CEO, Sarah Lindsell, has co-signed a letter to NHS organisations urging them to meet their one-year survival targets for the early diagnosis of brain tumours.

While Theresa May admits division in Westminster, our Chief Executive Sarah Lindsell says we must stand together stronger than ever to defeat brain tumours.

Trainee neurosurgeon at University Hospital Coventry and Warwickshire, Yasir Chowdhury, shines a light on day-to-day life in one of the most complex and dangerous areas of surgery and shares his hopes for finding a cure for brain tumours

From establishing a new cancer taskforce to ensuring benefits reviews take brain tumour patients into account, read our roundup of key activities from the past few weeks.

Last week Bristol-Myers Squibb announced the initial results from their Phase 3 clinical trial that was assessing the effectiveness and safety of the immunotherapy drug Nivolumab in patients with recurrent glioblastoma.

BrainPath is a surgical technique that uses the brain’s own tissue folds to tract a path to the tumour site. It is designed to be minimally invasive.

Ally Rooney posts an open letter to doctors, nurses, and allied health professionals who care for people with a brain tumour.

Last year, Greater Manchester became the first English region to gain control of health spending. Read our view on the impact this has had on charities.

Researchers at McGill University Health Centre (MUHC), Montreal have developed a new clinical approach to enhance the efficiency of treatment for glioblastomas, which increased the average survival time to 22 months.

The Imaging Centre of Excellence (ICE), was opened last Wednesday at the University of Glasgow, with the aim to be a global hub for precision medicine.

Diageo chose to support The Brain Tumour Charity following the sudden death of much loved colleague Mark Richardson.

Researchers at St. Jude Children’s Research Hospital, USA have revealed how a key protein involved in driving the growth of the most aggressive form of medulloblastoma also plays a role in stopping its development.

Scientists from The Institute of Cancer Research (ICR) have discovered 13 new genetic errors related with an increased risk of developing glioma in one of the largest ever studies of this devastating disease

On Sunday 26 March, the House of Lords Select Committee on Charities published a report, ‘Stronger charities for a stronger society’, following an inquiry into issues facing the charity sector in England and Wales.

A team of researchers from Northwestern University, USA have identified a molecule that could be used to inhibit the growth of the most fatal paediatric brain tumour, diffuse pontine intrinsic glioma (DIPG).

Over the last three years, The Brain Tumour Charity has expressed concerns about the assessment criteria used for Personal Independence Payments (PIPs), and their impact on people affected by a brain tumour.

Many news outlets are today reporting concerns from medical research institutions that childhood cancer patients in the UK will miss out on access to clinical trials for new treatments following Brexit.

Dr Thomas Ward, part of the Leeds Institute of Cancer and Pathology research team, is funded by various cancer charities including The Brain Tumour Charity.